News Sources quash rumours of an AZ/BMS mega-merger A media report suggests there is no substance to the rumours of a $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb.
News Pathos AI signs two cancer deals with Alphamab and AZ Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.
News Are we about to see a return for the pharma mega-merger? There are rumours that the first pharma 'mega-merger' for several years – between AstraZeneca and Bristol Myers Squibb – is under discussion.
News Datroway joins Trodelvy for frontline TNBC in the EU AstraZeneca and Daiichi Sankyo's Datroway enters the first-line triple-negative breast cancer market in the EU, taking on Gilead's Trodelvy.
News Ultomiris fail mars AZ's strong Q2 results AstraZeneca has served up a robust set of interim results, leavened by strong sales of cancer drugs, but with some mixed pipeline news on the side.
News EU clears AZ's SERD camizestrant, as FDA review drags on AstraZeneca's new breast cancer therapy Etcamah claims landmark frontline approval in the EU, but its prospects in the US are less certain.
News England close to eliminating hep C thanks to treatment drive England is on track to be one of the first countries in the world to eliminate hepatitis C, thanks to a national diagnosis and treatment programme.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
